RXFP1 receptor activation by relaxin-2 induces vascular relaxation in mice via a Gα(i2)-protein/PI3Kß/γ/nitric oxide-coupled pathway by Lian, X. et al.
fphys-09-01234 September 1, 2018 Time: 10:24 # 1
ORIGINAL RESEARCH
published: 04 September 2018
doi: 10.3389/fphys.2018.01234
Edited by:
Camille M. Balarini,
Federal University of Paraíba, Brazil
Reviewed by:
Ulf Simonsen,
Aarhus University, Denmark
Anna M. D. Watson,
Monash University, Australia
*Correspondence:
Maik Gollasch
maik.gollasch@charite.de
Specialty section:
This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology
Received: 27 May 2018
Accepted: 15 August 2018
Published: 04 September 2018
Citation:
Lian X, Beer-Hammer S, König GM,
Kostenis E, Nürnberg B and
Gollasch M (2018) RXFP1 Receptor
Activation by Relaxin-2 Induces
Vascular Relaxation in Mice via
a Gαi2-Protein/PI3Kß/γ /Nitric
Oxide-Coupled Pathway.
Front. Physiol. 9:1234.
doi: 10.3389/fphys.2018.01234
RXFP1 Receptor Activation by
Relaxin-2 Induces Vascular
Relaxation in Mice via a
Gαi2-Protein/PI3Kß/γ/Nitric
Oxide-Coupled Pathway
Xiaoming Lian1, Sandra Beer-Hammer2, Gabriele M. König3, Evi Kostenis3,
Bernd Nürnberg2 and Maik Gollasch1,4*
1 Experimental and Clinical Research Center (ECRC), Charité – University Medicine Berlin and Max Delbrück Center for
Molecular Medicine in the Helmholtz Association, Berlin, Germany, 2 Department of Pharmacology and Experimental
Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics,
and Interfaculty Center of Pharmacogenomics and Drug Research (ICePhA), Tübingen, Germany, 3 Institute for
Pharmaceutical Biology, University of Bonn, Bonn, Germany, 4 Medical Clinic for Nephrology and Internal Intensive Care,
Charité Campus Virchow Klinikum, Berlin, Germany
Background: Relaxins are small peptide hormones, which are novel candidate
molecules that play important roles in cardiometablic syndrome. Relaxins are
structurally related to the insulin hormone superfamily, which provide vasodilatory
effects by activation of G-protein-coupled relaxin receptors (RXFPs) and stimulation
of endogenous nitric oxide (NO) generation. Recently, relaxin could be demonstrated
to activate Gi proteins and phosphoinositide 3-kinase (PI3K) pathways in cultured
endothelial cells in vitro. However, the contribution of the Gi-PI3K pathway and their
individual components in relaxin-dependent relaxation of intact arteries remains elusive.
Methods: We used Gαi2- (Gnai2−/−) and Gαi3-deficient (Gnai3−/−) mice,
pharmacological tools and wire myography to study G-protein-coupled signaling
pathways involved in relaxation of mouse isolated mesenteric arteries by relaxins.
Human relaxin-1, relaxin-2, and relaxin-3 were tested.
Results: Relaxin-2 (∼50% relaxation at 10−11 M) was the most potent vasodilatory
relaxin in mouse mesenteric arteries, compared to relaxin-1 and relaxin-3. The
vasodilatory effects of relaxin-2 were inhibited by removal of the endothelium or
treatment of the vessels with N (G)-nitro-L-arginine methyl ester (L-NAME, endothelial
nitric oxide synthase (eNOS) inhibitor) or simazine (RXFP1 inhibitor). The vasodilatory
effects of relaxin-2 were absent in arteries of mice treated with pertussis toxin (PTX).
They were also absent in arteries isolated from Gnai2−/− mice, but not from Gnai3−/−
mice. The effects were not affected by FR900359 (Gαq protein inhibitor) or PI-103 (PI3Kα
inhibitor), but inhibited by TGX-221 (PI3Kβ inhibitor) or AS-252424 (PI3Kγ inhibitor).
Simazine did not influence the anti-contractile effect of perivascular adipose tissue.
Frontiers in Physiology | www.frontiersin.org 1 September 2018 | Volume 9 | Article 1234
fphys-09-01234 September 1, 2018 Time: 10:24 # 2
Lian et al. Relaxin-2 and Vasodilation
Conclusion: Our data indicate that relaxin-2 produces endothelium- and
NO-dependent relaxation of mouse mesenteric arteries by activation of RXFP1
coupled to Gi2-PI3K-eNOS pathway. Targeting vasodilatory Gi-protein-coupled RXFP1
pathways may provide promising opportunities for drug discovery in endothelial
dysfunction and cardiometabolic disease.
Keywords: serelaxin, relaxin-2, endothelial Gαi2, NO, RXFP1 receptor, perivascular-adipose tissue, ADRF
INTRODUCTION
Cardiometabolic syndrome is a combination of metabolic
dysfunctions mainly characterized by insulin resistance, impaired
glucose tolerance, dyslipidemia, hypertension, and central
adiposity. Relaxins were initially viewed as pregnancy hormones
because originally identified to be produced by the ovary corpus
luteum in pregnant women (Bell et al., 1987). Later relaxins were
also found to be produced in the heart, in the mammary gland,
in the endometrium (Kakouris et al., 1992; Du et al., 2010), in
the placental trophoblast cells and in the prostate (Hansell et al.,
1991). Relaxins are structurally related to the insulin hormone
superfamily, consisting of two peptide chains derived from a
common processor that are linked by two disulfide bridges. They
act through different relaxin family peptide receptors (RXFPs)
and signaling pathways (Dessauer and Nguyen, 2005). Humans
express three forms of relaxins encoded by three separate
genes, that is, relaxin-1 (RLX1), relaxin-2 (RLX2), and relaxin-3
(RLX3) genes. Relaxin-1 and relaxin-2 are the major circulating
relaxin isoforms in humans and other mammals (Grossman and
Frishman, 2010), while relaxin-3 is expressed at high levels in the
nucleus incertus in human and rodent brains, where it has been
postulated to act locally as a neuropeptide (Goto et al., 2001).
In recent years, there has been increasing interest in the
possible role of relaxins in cardiometabolic syndrome. Relaxin
treatment reduces food intake in rats (McGowan et al., 2010),
reverses insulin resistance and restored endothelial-dependent
vasodilatation in high-fat-diet mice (Bonner et al., 2013).
Moreover, RXFPs have been suggested to represent potential
targets for anti-anxiety and anti-obesity drugs (Halls et al.,
2007). Meanwhile, serelaxin (RLX030), the drug represents the
recombinant form of human relaxin-2, also shows promising
effects in the therapeutic process in patients with hypertension
(Papadopoulos et al., 2013), acute heart failure (AHF) (Teerlink
et al., 2013), and ischemic heart disease (Parikh et al., 2013),
most likely through its vasodilatory, antifibrotic, and antigenic
properties (Conrad, 2010).
Relaxins are capable of inducing vasodilation in human
(Fisher et al., 2002) and rodent microvessels (Conrad, 2010).
The effects are mediated via specific G-protein-coupled receptors
(GPCRs), the relaxin family peptide receptor (RXFP) 1–4
(Bathgate et al., 2006). RXFP1 is widely expressed in heart,
kidney, lung, liver, blood vessels, and various areas of the
brain. This GPCR is considered to be the fundamental RXFP
receptor to mediate relaxin effects in the cardiovascular system
by complex mechanisms and intracellular signaling pathways
(Bani-Sacchi et al., 1995; Nistri and Bani, 2003). Cell culture
experiments indicate that relaxin could activate endothelial nitric
oxide synthase (eNOS) via a pertussis toxin (PTX)-sensitive
Gi-PI3K-dependent pathway (Halls et al., 2006; Novak et al.,
2006; van der Westhuizen et al., 2008). However, it is unknown
whether this pathway is relevant to vasodilation of intact vessels.
It is also unknown which G proteins are involved in this
pathway. RXFP2 activates adenylate cyclase in recombinant
systems, but physiological responses are sensitive to pertussis
toxin. RXFP3 and RXFP4 resemble more conventional peptide
ligand receptors and both inhibit adenylate cyclase, and in
addition RXFP3 activates Erk1/2 signaling in vitro (Bathgate
et al., 2006). Although Gi-proteins have been suggested to
play important roles in cardiovascular disease, in particular in
ischemia reperfusion injury (Eisen et al., 2004), the involvements
of specific Gi isoform(s) [Gαi1, Gαi2, and/or Gαi3] and
vasodilatory GPCRs are unknown. This is particularly important
since there are only few reports that GPCRs are capable to
utilize Gi-coupled signaling pathways to cause vasodilation (i.e.,
for bradykinin, beta2 adrenergic agonists, thrombin) (Liao and
Homcy, 1993; Ciccarelli et al., 2007; Vanhoutte et al., 2017). It
is therefore not surprising that current research is focused on
the identification of novel compounds and GPCRs which can
utilize Gi-signaling pathways to produce potent relaxations. Since
relaxins are endogenous hormones, which could exhibit vascular
effects via Gi protein-coupled pathways (Halls et al., 2006; Novak
et al., 2006; van der Westhuizen et al., 2008), our study was
aimed to examine the putative vasodilatory effect of relaxins and
the involved G- and PI3K-dependent signaling pathways. In this
study, we compared the sensitivity of the three human relaxins
1–3 in eliciting relaxation of mouse mesenteric arteries and
tested the hypothesis that the NO-dependent vasodilatory effect
of relaxins is mediated by the activation of endothelial RXFP1
receptors, which are coupled to vasodilatory Gi2-PI3K-eNOS
signaling pathways. Finally, we also tested whether the RXFP1
pathway is involved in the periadventitial control of arterial tone
by perivascular adipose tissue (PVAT).
MATERIALS AND METHODS
Mice
Experiments were conducted according to the National Institutes
of Health Guide for the Care and Use of Laboratory Animals,
and the protocols were previously approved by the local Animal
Care and Use Committee from Berlin LAGeSo (G0132/14).
Animal experiments used 10- to 14-week-old mice of either
sex and were housed in groups of four to six animals in
cages with nesting material, mouse lodges, and open access
to water and feed, at 23◦C with a 12 h/12 h circadian
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cycle. Most experiments were performed using male wild-type
(WT, C57BL/6N) mice. To define Gαi isoforms involved in
relaxin effects, we used female Gαi2-deficient (Gnai2−/−) and
Gαi3-deficient (Gnai3−/−) mice and respective littermate (+/+)
controls. The generation and basal phenotypic characterization
of Gαi2-deficient and Gαi3-deficient mice are described elsewhere
(Rudolph et al., 1995; Gohla et al., 2007; Ezan et al., 2013; Wiege
et al., 2013).
Preparation of PTX-Treated Animals
Male wild-type C57BL/6 mice (20–25 g, 8–12 weeks) were
maintained according to national guidelines for animal care at
the animal facility. Mice were injected intraperitoneally with
150 µg/kg body weight pertussis toxin (PTX) or NaCl solution
(0.9 %) as vehicle control 48 h before use (Köhler et al., 2014).
Measurement of Vascular Reactivity by
Wire Myography
The second branches of mesenteric arteries were isolated from
mice under inhalation anesthesia with isoflurane and killed by
cervical dislocation. The vessels were then quickly transferred
to cold (4◦C) and oxygenated (95% O2/5% CO2) physiological
salt solution (PSS) containing (in mmol/L): 119 NaCl, 4.7
KCl, 1.2 KH2PO4, 25 NaHCO3, 1.2 MgSO4, 11.1 glucose, 1.6
CaCl2, and then dissected into 2 mm rings whereby perivascular
fat and connective tissue were either intact [(+) PVAT or
removed (−) PVAT] without damaging the adventitia. Each
ring was positioned between two stainless steel wires (diameter
0.0394 mm) in a 5-mL organ bath of a Small Vessel Myograph
(DMT 610M, Danish Myo Technology, Aarhus, Denmark)
(Fésüs et al., 2007). The software Chart5 (AD Instruments, Ltd.,
Spechbach, Germany) was used for data acquisition and display.
The rings were pre-contracted and equilibrated for 30 min until
a stable resting tension has been acquired. In some vessels, the
endothelium was removed mechanically by a whisker or an air
bubble (Fésüs et al., 2007). Endothelium integrity or functional
removal was confirmed by the presence or absence, respectively,
of the relaxant response to 1 µM acetylcholine (ACh) on
phenylephrine (PE 1 µM) pre-contracted arteries. Following PSS
wash, the pharmacological drugs were applied. After a waiting
period of 30 min, PE and subsequently relaxin-1 or -2 or -3 or
vehicle (PSS) was added to the bath solution. Relaxations induced
by relaxins were expressed as percentage relaxations obtained
with ACh (100%) or as percentage relaxations of PE contractions.
Contractions induced by PE were expressed as percentage tension
obtained with KCl-PSS (100%) containing (in mmol/L): 63.7
NaCl, 60 KCl, 1.2 KH2PO4, 25 NaHCO3, 1.2 Mg2SO4, 11.1
glucose, and 1.6 CaCl2. During the experiments, relaxin was
applied for at least 5 min, and data were recorded to ensure that
relaxins achieved their maximal effects (Willcox et al., 2013). All
drugs were added to the bath solution (PSS).
Materials
FR900359 was isolated as described previously (Schrage et al.,
2015). Salts and drugs have been purchased from Sigma-Aldrich
(Germany) with the exception of PTX and TGX 221, which were
obtained from Merck Millipore (Calbiochem) (Germany) and
PI-103 from Enzo Life Sciences. The PI3K inhibitors TGX-221,
AS-252424, and PI-103 were administered at submaximal
concentrations to achieve biological effects (Ali et al., 2008;
Tsvetkov et al., 2016a). All drugs were freshly dissolved on the
day of the experiment according to the material sheet. The relaxin
peptides have been purchased from Sigma-Aldrich (Germany).
Relaxins were dissolved in water. The following concentrations
were used: relaxin-1 at 10 pM or at 100 pM, relaxin-2 at 10 pM
or at 100 pM or from 1 pM to 10 nM, relaxin-3 at 10 pM or
at 100 pM.
Statistical Analyses
Results are presented as mean ± SEM. Data were analyzed
statistically using the GraphPad Prism 7 software (GraphPad
Software, San Diego, CA, United States). Unpaired Student’s
t-tests or ANOVA were used where appropriate. A value of P less
than 0.05 was considered statistically significant; n represents the
number of arteries tested.
RESULTS
Relaxation of Mesenteric Arteries by
Relaxin-1, Relaxin-2, and Relaxin-3
We first evaluated the vasoactive properties of the three different
relaxins, that is, relaxin-1, relaxin-2, and relaxin-3. Isolated
mesenteric artery rings were pre-contracted by phenylephrine
(PE 1 µM) and exposed to acetylcholine (ACh 1 µM) for control.
After wash-out of these substances, the vessels were re-exposed
to PE and subsequently incubated with relaxin-1, relaxin-2,
or relaxin-3 (at 10−10 M each) in separate vessels (Willcox
et al., 2013) (Figure 1). All three relaxins produced relaxations
(Figure 2A). However, relaxin-2, at the same concentration
tested, was more effective than relaxin-1 or relaxin-3 in producing
vasodilatory effects (Figure 2A). Importantly, this increased
efficiency for relaxin-2 was even more pronounced at 10-fold
lower concentrations (10−11 M; Figure 2B). Compared to ACh,
relaxations in response to relaxin-1, relaxin-2, and relaxin-3 were
slow and delayed (Figure 1). In order to exclude the possibility
that relaxations by relaxins result from a spontaneous loss of
the pre-contraction level, we performed control experiments
with vehicle (PSS) in arteries with and without endothelium.
Our results argue against this possibility (Figure 2). Removal of
the endothelium abolished both ACh and relaxin-2 relaxations
(Figure 1A, right). These data indicate that relaxins are powerful
peptide hormones to produce relaxations, probably utilizing an
endothelium-dependent mechanism distinct from ACh. Since
relaxin-2 was the strongest vasodilator, we continued the
following mechanistic studies using this relaxin peptide.
Relaxin-2 Causes RXFP-Induced
Relaxation via eNOS/NO Signaling
Without Involvement of Gαq Proteins
Figure 3 shows that the RXFP1 blocker simazine (100 nM)
inhibited relaxations induced by relaxin-2. Figure 4 shows
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FIGURE 1 | Effects of relaxins on mesenteric arteries. (A) Original representative recording for relaxin-2 induced relaxation with (left) and without endothelium (right).
(B) Original representative recording for relaxin-1 induced relaxation. (C) Original representative recording for relaxin-3 induced relaxation. PE, phenylephrine. ACh,
acetylcholine. For numbers of experiments, see Figure 2.
that the Gαq protein inhibitor FR900359 (100 nM) (Schrage
et al., 2015) inhibited concentration-dependent relaxations by
ACh (Figure 4B), but had no effect on relaxin-2-dependent
relaxations (Figure 4A). In these experiments, pre-tension was
induced by KCl-PSS, which causes membrane depolarization
to cause Ca2+ influx into vascular smooth muscle cells
and hence vasocontraction independently of Gαq protein
activation (Wirth et al., 2008). In contrast, the eNOS inhibitor
L-NAME (100 µM) inhibited both relaxin-2- and ACh-induced
relaxations (Figures 4A,B, respectively). Together, the data
indicate that both relaxin-2 and ACh produce relaxation by an
endothelial-dependent mechanism involving eNOS/NO release.
However, whereas ACh utilizes an eNOS/NO signaling pathway
involving muscarinic receptors coupled to Gq proteins (Kruse
et al., 2012), relaxin-2 stimulates RXFP1 receptors coupled to
G proteins other than Gq to produce eNOS/NO-dependent
relaxation.
Involvement of Gi Proteins in
Relaxin-2-Induced Relaxation
To determine a possible role of Gi proteins in relaxin-
2-dependent relaxation, we treated mice with pertussis
toxin (PTX), which is used as pan-Gαi-inhibitor in vivo
(Devanathan et al., 2015). Control mice were treated with 0.9%
NaCl only. Figure 5A shows that Gq-dependent relaxations
by ACh were preserved in mesenteric arteries treated with
PTX. However, relaxation in response to relaxin-2 were
abolished in mesenteric arteries from mice pre-treated with PTX
(Figures 5A,C) compared to control arteries (Figures 5B,C).
In contrast, relaxations in response to ACh were not changed
by PTX treatment (Figure 5D). The Gi-family comprises
three closely related Gα members, Gαi1−3, with Gαi2 and Gαi3
abundantly expressed in the cardiovascular system (Hippe
et al., 2015). We therefore used Gαi2-deficient (Gnai2−/−)
and Gαi3-deficient (Gnai3−/−) mice to determine which Gαi
isoforms are involved in relaxin-2 mediated relaxations. Figure 6
shows that relaxin-2 induced relaxations were reduced in
Gαi2-deficient arteries (Figures 6A,C) but not in Gαi3-deficient
arteries (Figures 6B,D). These data indicate that Gαi2 plays an
important role in RXFP1 mediated relaxations.
Involvement of PI3Kβ and PI3Kγ in
Relaxin-2-Dependent Relaxations
PI3K signaling has been proposed to mediate slow and sustained
activation of eNOS and subsequent NO release in cell culture
experiments (Dimmeler et al., 1999). We tested the contribution
of different PI3K isoforms in eNOS/NO-dependent RXFP1
receptor-mediated relaxations in comparison to ACh-induced
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FIGURE 2 | Summary data for relaxations induced by relaxins. (A) Summary data for % relaxation (PE) by 100 pM relaxin-1 (n = 6 rings out of 5 mice), 100 pM
relaxin-2 (n = 8 out of six mice), 100 pM relaxin-3 (n = 6 out of five mice), vehicle control in vessels with endothelium (n = 6 out of four mice), and vehicle control in
vessels without endothelium (n = 6 out of four mice) and for % relaxation relative to ACh (100%) response. Relaxin-1 (n = 6 out of five mice), relaxin-2 (n = 8 out of six
mice), relaxin-3 (n = 6 out of five mice), and vehicle control in vessels with endothelium (n = 6 out of four mice). (B) Summary data for % relaxation (PE) by 10 pM
relaxin-1 (n = 6 rings out of four mice), 10 pM relaxin-2 (n = 7 out of four mice), 10 pM relaxin-3 (n = 6 out of four mice), vehicle control in vessels with endothelium
(n = 6 out of four mice), and vehicle control in vessels without endothelium (n = 6 out of four mice) and for % relaxation relative to ACh (100%) response. Relaxin-1
(n = 6 out of four mice), relaxin-2 (n = 7 out of four mice), relaxin-3 (n = 6 out of four mice), and vehicle control in vessels with endothelium (n = 6 out of four mice).
∗P < 0.05 using one-way ANOVA followed by Bonferroni multiple comparisons test; n.s., not significant.
relaxations. Vessels were pre-contracted with PE, incubated with
L-NAME or various PI3K inhibitors and subsequently exposed to
relaxin-2 (Figure 7). Figures 7A,B shows that relaxin-2-induced
relaxations were inhibited by L-NAME. The PI3Kβ inhibitor
TGX-221 (Figure 7B) and the PI3Kγ inhibitor AS-252424
(Figure 7B) had similar inhibitory effects on stimulation by
relaxin-2. However, relaxin-2-induced relaxations were not
affected by the PI3Kα inhibitor PI-103 (Figure 7B). Together, the
data suggest that PI3K isoforms β and γ are essential intermediate
signaling components in eNOS/NO-dependent relaxation by
relaxin-2, which are controlled by relaxin-2 that act on RXFP1
receptors coupled to Gi2 proteins.
RXFP1 Activation by Relaxins Is Unlikely
Involved in Arterial Tone Regulation by
Perivascular Adipose Tissue
Perivascular adipose tissue (PVAT) plays a functional role
in regulating the contractile state of arteries by production
of numerous vasodilatory substances (Gollasch, 2017).
Since relaxin(s) are expressed in adipose tissue (Hausman
et al., 2006), these polypeptide hormones might represent an
adipose-derived relaxing factor released by PVAT to contribute
to anti-contractile effects on arterial tone. Therefore, we studied
vascular contractions in response to PE in arterial ring in the
presence and absence of PVAT. Figure 8 shows that in the
absence of PVAT phenylephrine was more potent in causing
effective contractions of arterial rings than in the presence of
PVAT. This anti-contractile effect of PVAT was not influenced
by the incubation of the arteries with the RXFP1-receptor
antagonist simazine (100 nM) (Figure 8). We also performed
control experiments on whether simazine or the other drugs
used in this study affect contractions caused by PE. The results
in Supplementary Figure S1 show that contractions caused
by PE in the absence (first PE application) and presence of the
respective drugs (second PE application) were not different. The
data demonstrate that neither simazine nor the other drugs used
in this study affected PE contractions.
DISCUSSION
Our study shows that relaxins are extremely potent (in
the low picomolar range) endothelium-dependent and
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FIGURE 3 | Effects of simazine on relaxin-2 induced relaxations. (A) Original
representative recording on relaxin-2 induced relaxation in the presence of
100 nM simazine. (B) Summary data for relaxin-2 induced relaxation in the
presence of 100 nM simazine (n = 9 out of six mice). ∗P < 0.05 using one-way
ANOVA followed by Bonferroni multiple comparisons test; n.s., not significant.
L-NAME-sensitive vasodilators in mouse mesenteric arteries.
Similar vasodilatory potencies of relaxins have been observed
renal arteries of rats (Novak et al., 2002) and human small
gluteal and subcutaneous arteries (Fisher et al., 2002). Among
the three human relaxins studied, we identified relaxin-2 as the
most effective vasodilator, which produces eNOS/NO-dependent
relaxation most likely due to activation of RXFP1 coupled to a
Gi2-PI3kβ/PI3kγ pathway. Although, we probed human relaxins
in a non-human vascular preparation, that is, in isolated arteries
from mice, this is the first study suggesting that RXFP1 coupled
to a Gi2-PI3kβ/PI3kγ pathway is capable of producing vascular
relaxation. Furthermore, our data indicate that this pathway does
not contribute to PVAT control of arterial tone.
Relaxin Family of Peptides
Relaxin-encoding genes are present in all mammals and
responsible for the production of the relaxin peptides that have
been initially found in circulating blood during pregnancy.
However, more recent studies have observed that relaxins
are produced in many tissues in mammals as paracrine or
autocrine factors to exert a number of different physiological
roles in the vasculature, which may exhibit protective effects in
cardiovascular disease (Samuel et al., 2006). The injection of
recombinant human relaxins to normotensive rats for 1 to 6 h
induced a systemic vasodilatory response (Debrah et al., 2005).
This finding suggests that certain vascular beds, for example, in
the kidney or mesentery, are able to respond by a vasodilatory
response caused by relaxins. Relaxin-2 has been identified as
the most important member of the relaxin family and major
circulating form of relaxin peptides in humans (Grossman and
Frishman, 2010). Relaxin-1 is also believed to exist as circulatory
peptide in the circulation (Bathgate et al., 2013), but the function
FIGURE 4 | Effects of FR900359 and L-NAME on acetylcholine and relaxin-2
induced relaxations. (A) Summary data for relaxin-2 induced relaxationsin
arteries in the presence of L-NAME (100 µM, 30 min) (•, n = 6 out of four
mice), in the presence of FR900359 (100 nM, 30 min) (, n = 6 out of four
mice), and in non-treated arteries (control group) (•, n = 6 out of four mice).
(B) Summary data for ACh-induced relaxations in arteries in the presence of
L-NAME (100 µM) (•, n = 6 out of four mice), in the presence of FR900359
(100 nM) (, n = 6 out of four mice), and non-treated arteries (control group)
(, n = 6 out of four mice). ∗P < 0.05 for relaxin-2 + L-NAME vs. control or
ACh + L-NAME vs. non-treated vessels or ACh + FR900359 vs. non-treated
vessels; repeated-measures two-way ANOVA, followed by Bonferroni post
hoc test.
of the relaxin-1 in humans and higher primates is mostly unclear.
Relaxin-3 is the most recently identified member of the relaxin
family and is primarily expressed in the brain of mammals
(Heidari et al., 2018). In our study, we first tested the vasoactive
function of all three relaxins in mouse mesenteric arteries.
We found that all three relaxins can produce relaxations, with
relaxin-2 being the most effective member of the relaxin family.
In contrast to ACh, which produces a rapid relaxation, relaxin-1,
relaxin-2, and relaxin-3 induced slow and delayed relaxations,
indicating different underlying signaling mechanisms between
ACh and relaxins to cause endothelium-dependent relaxations.
Frontiers in Physiology | www.frontiersin.org 6 September 2018 | Volume 9 | Article 1234
fphys-09-01234 September 1, 2018 Time: 10:24 # 7
Lian et al. Relaxin-2 and Vasodilation
FIGURE 5 | Effects of treatment of mice with pertussis toxin (PTX) or sham (0.9% NaCl) on relaxin-2 relaxations. (A) Original representative recording of relaxin-2
induced relaxations in arteries of PTX treated mice. (B) Original representative recording of relaxin-2 induced relaxations in arteries of 0.9% NaCl treated (control)
mice. (C) Summary data of relaxin-2 induced relaxation. (D) Summary data of ACh induced relaxation. PTX group; n = 11 out of eight mice. 0.9% NaCl group; n = 7
out of four mice. ∗P < 0.05 using unpaired t-test; n.s., not significant.
Relaxin-2 Exerts Relaxation by Activating
RXFP1 in Endothelium
Studies on isolated vessels have shown that the endothelium
is necessary for vasodilation by relaxin in renal and human
subcutaneous arteries (McGuane et al., 2011). In our study on
mouse mesenteric arteries, we also found that removal of the
endothelium or treatment with L-NAME inhibited relaxation by
relaxin-2. Our data support previous findings indicating that
relaxins cause vasodilation primarily by an eNOS/NO-dependent
mechanism (McGuane et al., 2011; Ng et al., 2015; Leo
et al., 2016). Relaxin produces its major effects via specific
G-protein-coupled receptors (GPCRs), that is, RXFP 1-4 (Hsu
et al., 2002; Bathgate et al., 2006). Among them, RXFP1 was the
first to be identified and remains in focus of interest because
of its crucial role in the cardiovascular system (Bathgate et al.,
2013). RXFP2 receptors are mainly activated by insulin-like
(INSL) 3 in the gubernaculum to facilitate testicular descent into
the scrotum, and RXFP3 and RXFP4 receptors are activated by
relaxin-3 and INSL5, respectively (van der Westhuizen et al.,
2008). RXFP1 has the highest binding potency for relaxin-2
within the several members of the relaxin peptide family (Samuel
et al., 2006; Nistri et al., 2007). RXFP1 is predominantly expressed
in endothelial cells of mesenteric arteries and veins, but also
expressed in the aorta and vena cava (Novak et al., 2006; Jelinic
et al., 2014). In our experiments, the RXFP1 antagonist simazine
(Park et al., 2016) largely inhibited the endothelium-dependent
relaxation induced by relaxin-2, which supports the idea that
relaxin-2 produces relaxation primarily through binding to
and activation of RXFP1 in the endothelium (Figure 9). The
remaining relaxation of about 25% in simazine-treated vessels
may represent spontaneous relaxation or caused by RXFP
activation distinct from RXFP1 in the vasculature or both of
them.
Relaxin-2 Induces eNOS/NO-Dependent
Vasodilation Through a Gi2-PI3Kβ/PI3Kγ
Pathway
We aimed to identify the G proteins coupled with RXFP1 to cause
eNOS/NO-dependent vasodilation by relaxin-2. Heterotrimeric
G proteins, which mediate signals from cell surface receptors
to cellular effectors, are composed of α, β, and γ subunits,
of which Gα defines the class of G proteins (Simon et al.,
1991). The α subunits that define the basic properties of a
heterotrimeric G protein can be divided into four families,
namely Gs, Gq/G11, Gi/Go, and G12/13 (Kaziro et al., 1988;
Wettschureck and Offermanns, 2005). ACh produces relaxation
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FIGURE 6 | Vasorelaxant effects of relaxin-2 in Gαi2 deficient (Gnai2−/−), Gαi3 deficient (Gnai3−/−), and control arteries. (A,B) Original representative recordings.
(C) Summary of data. Gαi2 deficient arteries; n = 9 out of five mice. Control; n = 9 out of four mice. (D) Summary of data. Gαi3 deficient arteries; n = 6 out of five
mice. Control arteries; n = 7 out of four mice. ∗P < 0.05 using unpaired t-test.; n.s., not significant.
mainly via the Gq/G11-coupled M3 receptor subtype (Figure 9)
(Jaiswal et al., 1991; Kruse et al., 2012). In our study, we found
that ACh-induced relaxations were abolished by FR900359, a
selective mammalian Gq/G11 signaling inhibitor (Schrage et al.,
2015), while the relaxin-2-induced relaxations were not blocked
by this drug. We conclude that vasodilatory RXFP1-coupled G
proteins are distinct from Gq/G11 (Figure 9). Our data using
the pan Gi/Go inhibitor PTX (Simon et al., 1991) indicate that
Gi/Go proteins could play a major role in relaxin-2 mediated
vasodilation. G0 is particularly abundant in the neuronal and
the neuroendocrine system and the Gi-family includes three
closely related Gα members, Gαi1−3, which display overlapping
expression patterns with Gαi2 and Gαi3, abundantly expressed
in the cardiovascular system (Hippe et al., 2015). According to
previous studies on cultured cells, RXFP1 has been suggested
to couple to Gαi3 to release Gβγ dimers to activate the PI3K
pathway via Akt phosphorylation and subsequently initiate NOS
(Halls et al., 2006; McGuane et al., 2011). Our experiments using
Gαi2-deficient (Gnai2−/−) and Gαi3-deficient (Gnai3−/−) mice
failed to implicate an important role of Gαi3, but revealed a
key role of Gαi2 in RXFP1-eNOS/NO relaxation. We found
that relaxin-2 induced relaxation was impaired in arteries from
Gnai2−/−, but not from Gnai3−/− mice. Although structural
similarity between the three Gi subforms suggests that they
may exhibit overlapping functions, Gαi2/Gαi3-double-deficient
mice cannot be used for myography experiments because they
die in utero at early embryonic stages. Nevertheless, present
data obtained in mice lacking Gαi2 or Gαi3 indicate distinct
biological key roles of these two Gαi-isoforms (Köhler et al.,
2014). Thus, we believe that relaxin-2 relaxes mouse mesenteric
arteries primarily via RXFP1 activation and coupling to Gi2 but
not Gi3 (Figure 9). Moreover, since the pan Gi/Go inhibitor PTX
shows a stronger inhibitory effect than the absence of Gαi2, we
should also consider that relaxin-2 could partly act through other
Gi proteins.
Following the release of Gβγ from Gαi, it was recently
suggested that the class I PI3K represents a target for Giβγ
signaling by relaxins (McGuane et al., 2011). Accordingly, we
found that eNOS activation by relaxin was inhibited by the
pan PI3K inhibitors Wortmannin or LY294002 in cultured
endothelial cells (Dessauer and Nguyen, 2005). Based on
the association with non-catalytic binding proteins, catalytic
subunits of class I PI3Ks are subdivided into class IA-isoforms
(p110α, -β, and -δ ) or class IB p110γ (Hennessy et al.,
2005). In this study, we found that relaxin-2-RXFP1 relaxation
was inhibited by the PI3Kγ and PI3Kβ inhibitors AS-252424
and TGX-221, respectively. The PI3Kα inhibitor PI-103 had
no effects. These data indicate that class I PI3Kγ and PI3Kβ
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FIGURE 7 | Effects of PI3K inhibitors on relaxin-2 induced relaxation.
(A) Original representative recording. (B) Summary of data. Relaxin-2-induced
relaxation in the presence of 100 µM L-NAME (n = 6 out of four mice), 100 nM
AS-252424 (n = 7 out of four mice), 100 nM TGX-221 (n = 7 out of four mice),
or 100 nM PI-103 (n = 6 out of four mice). ∗P < 0.05 using one-way ANOVA
followed by Bonferroni multiple comparisons test; n.s., not significant.
FIGURE 8 | Effects of simazine on phenylephrine (PE)-dependent
contractions in the presence (+) or absence (−) of perivascular adipose tissue
(PVAT). Summary data for PE induced contractions in (+) PVAT (•, n = 8 out of
four mice) or (−) PVAT (, n = 8 out of four mice) rings. Incubation of the rings
with simazine (100 nM, 30 min) had no effects on contractions caused by PE
in (+) PVAT (•, n = 8 out of four mice) and (−) PVAT (, n = 9 out of 4 mice)
arterial rings (P > 0.05 each). ∗P < 0.05 for (−) PVAT vs. (+) PVAT or (−) PVAT
+ Simazine vs. (+) PVAT + Simazine; repeated-measures two-way ANOVA,
followed by Bonferroni post hoc test.
represents likely a target for Gi2 signaling by relaxins to cause
eNOS/NO dependent relaxation. We are not aware of selective
PI3kδ inhibitors to determine a possible additional role of
PI3Kδ in RXFP1-mediated relaxation. Nevertheless, our data
indicate that class I PI3K activation by a target for RXFP/Gi-βγ
signaling to cause eNOS activation is not only a cell culture
phenomenon (Dimmeler et al., 1999; Dessauer and Nguyen,
2005), but is important for relaxins to produce vascular relaxation
(Figure 9). Of note, the relaxin-2-induced relaxations were not
fully abolished by TGX-221 or AS-252424. This may indicate
that both PI3K isoforms or another PI3K isoform are involved
in this vasoregulatory pathway. Also, in addition to the slow
activation process of the eNOS/NO by relaxins via Gi-PI3K
(McGuane et al., 2011), there is also an ultra-slow mechanism
of eNOS/NO stimulation via κ upon exposure of cultured
endothelial cells to relaxin (Dschietzig et al., 2003). Although this
putative mechanism cannot be examined by the methodological
approach used in our study, such non-RXFP-mediated effects
may contribute to the effects of relaxins in the vasculature
in vivo.
Microarray studies showed expression of relaxin in pig
adipose tissue (Hausman et al., 2006). According to our
previous studies, PVAT inhibits vessel contraction and
produces endothelium-independent relaxation by releasing
adipocyte-derived relaxing factor (ADRF) (Löhn et al., 2002;
Dubrovska et al., 2004; Verlohren et al., 2004; Tsvetkov et al.,
2016b). PVAT dysfunction is characterized by disturbed
secretion of various adipokines, which, together with endothelial
dysfunction, contribute to hypertension and cardiovascular
risk (Lian and Gollasch, 2016). With our interest, we aimed
to unravel whether relaxin(s) acting through RXFP1 receptors
may represent an ADRF. Our data showed that the RXFP1
antagonist simazine does not influence the anti-contractile
effects of PVAT, which indicates that it is unlikely that
relaxin(s) acting though RXFP1 receptors contributes to
PVAT control of arterial tone, at least in mouse mesenteric
arteries.
Limitations
There are a number of limitations in the present study. First,
we studied human relaxins rather than mouse relaxins to
identify Gi protein-dependent vasodilatory pathways in the
murine vasculature. Utilizing the murine vasculature enabled
us to use advance of transgenic mouse models. Since serelaxin
(RLX030) represents the recombinant form of human relaxin-2,
which shows quite reliable therapies in cardiovascular diseases
(Papadopoulos et al., 2013; Parikh et al., 2013; Teerlink et al.,
2013), we are aimed to identify the function and mechanisms
of RXFP1signaling pathways utilized by human relaxins in
the vasculature. Of note, human relaxin-2 (H2 relaxin) is
the counterpart of mouse relaxin-1 (M1 relaxin) within the
structurally related insulin/relaxin superfamily, and mouse
RXFP1 shows 89% identity to human RXFP1 (Sherwood, 2004;
Kong et al., 2010). Binding of relaxins to RXFP1 is mediated
via high-affinity binding to extracellular domain of RXFP1
and an additional binding site in the transmembrane (TM)
exoloops (Sherwood, 2004). A recent study has shown that
specific residues in the center of the H2 relaxin A-chain are
necessary for ligand activity at RXFP1 (Park et al., 2008).
Importantly, modeling of the ligand–receptor interaction for
different RXFP receptors suggests that once the B-chains of
the ligands are bound to the primary binding site in a
large ectodomain with 10 leucine-rich repeats (LRRs) that the
A-chain is presented in a favorable orientation for interaction
with the TM exoloops (Hartley et al., 2009). Hence, it is
likely that human and murine relaxins utilize similar common
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FIGURE 9 | Proposed vasodilatory pathways caused by relaxin-2. Relaxin-2 activates RXFP1 (blocked by simazine), which leads to Gi2 activation and dissociation of
Gαi2 and βγ subunits (blocked by PTX). Gβγ subunits in turn activate PI3Kβ (blocked by TGX-221) and PI3Kγ (blocked by AS-252424) to initiate eNOS activation
and NO release (blocked by L-NAME) to cause relaxation. PI3Kα (blocked by PI-103) seems not to be involved in this pathway. On the other hand, ACh binds to
muscarinic M3 receptors coupled to Gq/11 (blocked by FR900359) to produce eNOS/NO dependent arterial relaxation.
mechanisms to activate RXFP1 receptors, although there might
be species-dependent differences in the mode of interaction
between the individual relaxins, extracellular RXFP1 domains
and the TM exoloops of the individual receptors. Second, we
used female instead of male Gnai2−/− and Gnai3−/− mice and
respective littermate controls. Because of the estrous cycle in
females, there could be gender-related differences of the vascular
reactivity and endothelial function (Sader and Celermajer,
2002), which should be considered. Nevertheless, our data
clearly demonstrate a genotype-dependent inhibition of relaxin-2
relaxations, that is, lack of relaxin-2 relaxation in arteries from
Gnai2−/−, but not from Gnai3−/− mice. Lastly, considering
that inhibition of endothelium may have influence on PE
pre-contraction levels, for example, by mitogen-activated protein
kinase kinase/extracellular signal-regulated kinase-dependent
mechanisms (Molnar et al., 2008), we compared relaxin
relaxations with ACh relaxations also in KCl-precontracted
vessels. Our data show relaxin-2 relaxations involve an
RXFP1-Gi protein pathway in both conditions. The Gq
inhibitor FR900359 did not inhibit relaxin-2 relaxations and
PE contractions were not affected the drugs used in our
study (Supplementary Figure S1). Nevertheless, removal of the
endothelium may stabilize the level of pre-contraction to play
an additional role in eliminating endothelium-dependent RXFP1
relaxations.
CONCLUSION
In summary, we provide evidence that all three relaxins, that
is, relaxin-1, relaxin-2, and relaxin-3, are potent vasodilators
in mesenteric arteries of mice. Among them, relaxin-2 is the
strongest vasodilator, which produces relaxation via activation
of endothelial RXFP1 coupled to a Gi2-PI3Kγ/β-eNOS/NO
pathway. Based on the fact that long- and intermediate-distance
conduction of vasodilation is common in the circulation,
localized releases of relaxins within a tissue might be able
to produce remote vasodilations in regions of reduced blood
flow distribution. As a potent vasodilatory Gαi2-coupled
receptor, targeting RXFP1 may represent a promising avenue
to study Gi-coupled receptor based drugs in cardiovascular
disease that may allow clarifying specific roles for Gαi2
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and Gαi3 in response to GPCR activation directly in the
vasculature.
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